Compare Tango Therapeutics Inc. (TNGX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vistra Corp — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Vistra Corp trades at $147.77 (market cap $54.49B). The key difference: Vistra Corp is far larger — about 14.5× Tango Therapeutics Inc.'s market cap, and Vistra Corp pays a 0.57% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vistra Corp for 33 Days on average.
| TNGX | VST | |
|---|---|---|
Market Cap | $3.75B | $54.49B |
Volume | 9,619,106 | 5,289,982 |
Sector | Health | Utilities |
52-Week High | $32.90 | $210.85 |
52-Week Low | $7.50 | $134.71 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $2.77B | $76.43B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Vistra Corp (VST) trades at $162.36, up 2.68% with strong institutional support and bullish technical indicators. The stock shows impressive profitability with 75.73% ROE and 11.55% net margin, though recent earnings were mixed with Q1 beat but Q2 miss. Recent developments include a $4.2 billion government loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra presents significant upside potential with a $215.23 consensus price target (32.5% upside) and 91.3% buy ratings. The company benefits from nuclear power expansion and AI infrastructure demand, though risks include execution of growth initiatives and energy market volatility. Current valuation at 27.38 P/E appears reasonable given growth prospects in the power generation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
